Protection from cyclophosphamide-induced ovarian damage with bone marrow-derived mesenchymal stem cells during puberty

dc.authorid0000-0002-5780-8209
dc.authorid0000-0002-1034-614X
dc.authorscopusid55666290500
dc.authorscopusid56602651500
dc.authorscopusid6603871718
dc.authorscopusid23986422400
dc.authorscopusid56016938100
dc.authorscopusid55893004100
dc.authorwosidDELIBASI, TUNCAY/ABE-5351-2021
dc.contributor.authorKılıç, Sevtap
dc.contributor.authorPinarli, Ferda
dc.contributor.authorÖzögül, Candan
dc.contributor.authorTaşdemir, Nicel
dc.contributor.authorSarac, Gülce Naz
dc.contributor.authorDelibaşı, Tuncay
dc.date.accessioned2022-05-11T14:35:52Z
dc.date.available2022-05-11T14:35:52Z
dc.date.issued2014
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalı
dc.description.abstractObjective: In female cancer survivors, the accelerated loss of primordial follicles may lead to premature ovarian failure. We investigated the protective effects of bone marrow derived mesenchymal stem cells (BMMSC) and gonadotropin releasing hormone analogue (GnRHa) against chemotherapeutic-induced ovarian toxicity in a rat model. Material and methods: Forty-eight Wistar albino female rats were divided into four groups. Group 1 was composed of rats that were given 200 mg/kg cyclophosphamide injection for each cycle (two cycles for each rat). Both cyclophosphamide and 0.4 mu g GnRHa were administered to Group 2. Cyclophosphamide and 4 million/kg BMMSC were administered to Group 3. Cyclophosphamide, GnRHa, and BMMSC were administered to Group 4. Germ cell apoptosis, DNA fragmentation and primordial follicular count were investigated with Cleave Caspase-9 and TUNEL analysis. The presence of the SRY gene on the Y chromosome in the ovary of the recipient female rats was checked with PCR. Results: Immunohistochemical staining (IHS) of Caspase-9 and TUNEL was higher in Group 1 than in Group 3 (p<0.05). Similarly, Group 4 had higher values than Group 3 (p<0.05). The presence of the SRY gene was detected in Groups 3 and 4 with the PCR analysis. The mean primordal follicle count was lowest in Group 1 and the mean primordial follicle counts were higher in Groups 2 and 3 than in Group 1. The difference between Group 1 and Group 4 was not significant. Conclusion: BMMSC therapy was found to be protective from germ cell apoptosis and DNA damage when it was used with chemotherapy regimens including alkylating agents.
dc.identifier.doi10.3109/09513590.2013.860127
dc.identifier.endpage140
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue2en_US
dc.identifier.pmid24308768
dc.identifier.scopus2-s2.0-84893044553
dc.identifier.scopusqualityQ2
dc.identifier.startpage135
dc.identifier.urihttps://doi.org/10.3109/09513590.2013.860127
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8268
dc.identifier.volume30
dc.identifier.wosWOS:000330586000012
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTaşdemir, Nicel
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofGynecological Endocrinology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectApoptosis
dc.subjectchemotherapy
dc.subjectchildhood cancer
dc.subjectmesenchymal stem cell
dc.subjectpuberty
dc.subjectFunction Following Chemotherapy
dc.subjectHodgkins-Disease
dc.subjectHormone Agonist
dc.subjectCancer
dc.subjectFertility
dc.subjectPrevention
dc.subjectFailure
dc.subjectYoung
dc.subjectRat
dc.subjectPreservation
dc.titleProtection from cyclophosphamide-induced ovarian damage with bone marrow-derived mesenchymal stem cells during puberty
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8268.pdf
Boyut:
1001.64 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text